Conversion Surgery Following Combination Treatment With Immune Checkpoint Inhibitors and Chemotherapy for Initially Unresectable Gastric Cancer

医学 化疗 癌症 内科学 腹部外科 心胸外科 肿瘤科 心脏外科 血管外科 外科 免疫疗法 免疫系统 免疫检查点 联合化疗 胃切除术 胃肠病学
作者
Masaaki Nishi,Yuma Wada,Chie Takasu,Takuya Tokunaga,Toshihiro Nakao,Hideya Kashihara,Toshiaki Yoshimoto,Mitsuo Shimada
出处
期刊:World Journal of Surgery [Springer Science+Business Media]
卷期号:50 (6): 1631-1638 被引量:2
标识
DOI:10.1002/wjs.70372
摘要

AIM: Conversion surgery (CS) for unresectable advanced gastric cancer (GC; clinical stage IVb) has increased in recent years owing to advances in drug therapy. However, little is known about CS following combination treatment with immune checkpoint inhibitors (ICIs) and chemotherapy. METHODS: We conducted a retrospective cohort study of patients initially unresectable metastatic GC. We treated 36 patients with initially unresectable metastatic GC. Thirty-four patients received combination treatment with ICIs and chemotherapy, 11 of whom underwent CS. We evaluated their short-term and long-term surgical outcomes. RESULTS: Among patients who underwent CS, six were male and five female, and the median (interquartile range) age was 71 (47-75) years. All patients started first-line therapy with S-1 plus oxaliplatin combined with nivolumab, and two patients underwent surgery after second-line treatment with ramucirumab and nanoparticle albumin-bound paclitaxel. There were four open, two laparoscopic, and five robotic surgeries. The median operative time was 348 (321-354) minutes, blood loss was 16 (10-30) mL, and number of retrieved lymph nodes was 38 (27-44); there were no cases of conversion to laparotomy. R0 resection was achieved in all patients. And postoperative pathology was complete response; three patients, ypStage I; four patients, II; three patient, III; zero patient IV; one patient. ICI and chemotherapy efficacy was Grade 1 in four patients, Grade 2 in two patients, and Grade 3 in five patients. Overall 2-year survival was 90.0% for those who underwent CS. CONCLUSION: CS following combination treatment with ICI and chemotherapy may be promising for initially unresectable metastatic GC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
悦耳的怀寒完成签到,获得积分10
1秒前
1秒前
2秒前
kevin完成签到,获得积分10
2秒前
3秒前
芒果彩虹猪完成签到,获得积分10
3秒前
Wu发布了新的文献求助10
4秒前
无花果的应助被ying采纳,获得10
5秒前
Arya完成签到 ,获得积分10
5秒前
上官若男的应助被LiSJ采纳,获得10
5秒前
6秒前
yimuchenlin完成签到,获得积分10
6秒前
Hello的应助被wxr的boy采纳,获得10
6秒前
8秒前
李长安完成签到,获得积分10
8秒前
嗷嗷ao发布了新的文献求助10
8秒前
8秒前
科研通AI6.2的应助被jarrett采纳,获得10
8秒前
Qvby3完成签到 ,获得积分10
9秒前
康阿蛋发布了新的文献求助10
10秒前
10秒前
亚琛求文献完成签到,获得积分10
10秒前
11秒前
小鹿啊完成签到,获得积分10
11秒前
于玕完成签到,获得积分20
11秒前
yize发布了新的文献求助10
12秒前
12秒前
橡皮鱼发布了新的文献求助10
13秒前
Ronin完成签到,获得积分10
13秒前
14秒前
科研通AI2S的应助被康阿蛋采纳,获得10
14秒前
嘻嘻嘻完成签到,获得积分10
14秒前
YXHTCM发布了新的文献求助10
15秒前
哇呀呀发布了新的文献求助10
15秒前
在水一方的应助被冷酷的松采纳,获得10
16秒前
min完成签到,获得积分20
16秒前
16秒前
木夫贝发布了新的文献求助10
16秒前
叶财财完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621